Consistency of efficacy results across various clinical measures and statistical methods in the lecanemab phase 2 trial of early Alzheimer’s disease
Shobha Dhadda(Eisai (United States)), Donald A. Berry(Berry & Associates (United States)), Chad J. Swanson(Eisai (United States)), David Li(Eisai (United States)), Michael C. Irizarry(Eisai (United States)), Michio Kanekiyo(Eisai (United States)), Lynn D. Kramer(Eisai (United States)), Scott Berry(Queen's University)
Cited by 37
Related Papers
Derivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
|JAMA|2019|1.5k
Revision of the American Joint Committee on Cancer Staging System for Breast Cancer
|Journal of Clinical Oncology|2002|1.2k
Comparison of Antiarrhythmic Drug Therapy and Radiofrequency Catheter Ablation in Patients With Paroxysmal Atrial Fibrillation
|JAMA|2010|1.2k
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
|New England Journal of Medicine|2013|980
Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice
|Nature Neuroscience|1999|938